Tobacco Legislation Euthanasia Policy Tobacco Regulation Education Policy Drug Policy Tobacco Policy Nutrition Policy Agricultural Policy Youth Legislation Pandemic Response Vaccine Mandates Structural Reforms Government Accountability Preventive Strategies International Health Standards Drug Safety Policy Ayurveda Promotion Public Opinion Cannabis Legalization Criminal Justice Reform Crisis Management Drug Regulation Policy Demographic Policy Social Policy Food Policy Daylight Saving Time Debate Epidemiology Substance Regulation Mental Health Policy Care System Reform Research Funding Policy Regulatory Oversight Vaping Legislation Environmental Policy Social Security Prison Policy Workplace Regulations Tobacco Control Policy Child Health Drug Regulation Public Health Issues Cannabis Policy Youth Protection Infrastructure Development Public Health Initiatives Medical Admissions Drug Legislation Substance Abuse Policy Government Response Government Proposals Abortion Regulation NHS Funding
Want to see what podcasts are saying about this topic? Search across 140K+ podcasts. Explore Radar
The agency says the move will target concentrated and lab‑made 7‑hydroxymitragynine products because regulators link them to rising poisonings and local overdose deaths.
